LiverMultiScan

by Perspectum  · Based in United Kingdom → — A new way to see precision health. We deliver advanced imaging solutions that can help doctors make better decisions, personalize care for patients, and ensure better outcomes.
Gastroenterology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Not available
Regulatory Status Disclosed

Overview

LiverMultiScan is a non-invasive, MRI-based software application that provides quantitative metrics for a comprehensive assessment of liver health. It measures Corrected T1 (cT1), Proton Density Fat Fraction (PDFF), and Liver Iron Concentration (LIC) to characterize liver tissue, including inflammation, fibrosis, fat content, and iron concentration. This FDA-cleared and CE-marked precision imaging solution aids physicians in the diagnosis, risk stratification, and monitoring of chronic liver diseases like Metabolic dysfunction-associated steatotic liver disease (MASLD) and Metabolic dysfunction-associated steatohepatitis (MASH), as well as autoimmune and viral hepatitis. The cloud-based service integrates seamlessly with existing MRI systems (Siemens, GE, Philips at 1.5T and 3T) and DICOM image exchange platforms, delivering patient-centric reports without the need for contrast agents or additional hardware installation.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Non-invasive MRI-based liver assessment
  • Quantitative metrics: Corrected T1 (cT1), Proton Density Fat Fraction (PDFF), Liver Iron Concentration (LIC)
  • Measures liver fat, iron, inflammation, and fibrosis
  • Aids in diagnosis and risk stratification of liver disease
  • Predictive of liver and cardiovascular outcomes (cT1)
  • Standardized across major MRI platforms (Siemens, GE, Philips at 1.5T and 3T)
  • Contrast-free scanning
  • Automated DICOM data transfer for integration
  • Patient-centric, easy-to-understand reports
  • Cloud-based service with regional deployments

Use Cases

  • Diagnosis and management of MASLD/MASH
  • Monitoring treatment response in chronic liver diseases
  • Risk stratification for liver and cardiovascular disease
  • Assessment of autoimmune hepatitis
  • Evaluation of viral hepatitis and pediatric liver disease
  • Support for clinical trials in liver and metabolic diseases

What Physicians Need to Know

Procedure Documentation
LiverMultiScan generates comprehensive, easy-to-understand reports that provide quantitative metrics of liver health, aiding physicians in diagnosis and management of liver disease.
Quality Metrics Tracking
The tool provides quantitative metrics such as corrected T1 (cT1), proton density fat fraction (PDFF), and liver iron concentration (LIC), which are crucial for monitoring disease activity, fat content, iron concentration, and tracking the progression of liver disease and response to treatment.
Physician Tip

LiverMultiScan is a non-invasive, MRI-based diagnostic aid for assessing liver health, providing quantitative measures of fat, iron, inflammation, and fibrosis. It is particularly useful for diagnosing and monitoring chronic liver diseases, including nonalcoholic steatohepatitis and autoimmune hepatitis, and can serve as a cost-effective alternative to liver biopsies for long-term monitoring. Interpret the generated reports in conjunction with other clinical information for comprehensive patient management.

LiverMultiScan is a software application that processes MRI data. It is compatible with existing MRI machines from manufacturers like Siemens, GE, and Philips (at both 1.5 and 3 Tesla). Data transfer is facilitated through DICOM 3.0 compliant image exchange platforms, including native support for systems like Ambra and Powershare, simplifying integration into existing radiology workflows.

Details

Category Gastroenterology AI
Pricing Not available — Not specified
DeploymentCloud-based service. No software or hardware installation required at the MRI site, utilizes existing manufacturer software and DICOM image exchange platforms. Hosted in regional US data centers, with UK and EU options available.
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Yes AI-estimated

LiverMultiScan (K202170) is a Class II Magnetic Resonance Diagnostic Device (product code LNH) cleared via 510(k) for non-invasive liver evaluation. It enables the generation, display, and review of 2D magnetic resonance medical image data and pixel maps for MR relaxation times, assisting in the diagnosis and monitoring of liver disorders, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Integrations
EHR Not specified
Specialties Gastroenterology, Radiology

What the Web Says

LiverMultiScan, developed by Perspectum, is a quantitative MRI-based technology designed to provide a comprehensive assessment of liver health, including fat, iron, and fibrosis. It aims to offer a non-invasive alternative or complement to liver biopsy, aiding in the diagnosis and monitoring of various liver diseases like NAFLD/NASH. Reviews highlight its potential for early detection and disease management.

Overall: Positive

Strengths

  • Non-invasive alternative to liver biopsy, reducing patient risk and discomfort.
  • Provides quantitative metrics (cT1, PDFF, R2*) for fat, iron, and fibrosis, offering a comprehensive liver assessment.
  • Useful for monitoring disease progression and treatment response in conditions like NAFLD/NASH.
  • Standardized and reproducible results, improving consistency across different sites.
  • Potential for earlier detection and intervention in liver diseases.
  • Reduces the need for multiple imaging modalities by providing a multi-parametric assessment.

Limitations

  • Cost of the MRI scan and specialized analysis can be a barrier for some healthcare systems or patients.
  • Requires specialized MRI equipment and trained personnel for acquisition and interpretation.
  • Availability may be limited to larger medical centers or specialized imaging facilities.
  • Interpretation still requires clinical context and expertise, not a standalone diagnostic tool.
  • Patient compliance with MRI protocols (e.g., breath-holding) can sometimes be an issue.
  • Some physicians may still prefer biopsy for definitive diagnosis in certain complex cases.

Based on reviews from: Perspectum Official Website, Clinical Research Papers and Journals (e.g., Journal of Hepatology, Gastroenterology), Healthcare IT News, Physician Forums and Conferences, Reddit (medical subreddits), G2 (no direct reviews found for this specific medical device, but general healthcare tech reviews), Capterra (no direct reviews found for this specific medical device, but general healthcare tech reviews)

Last updated: 2026-07-22

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate LiverMultiScan

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Perspectum
New Multinational Study Shows MRI is Cost-Effective in the Diagnosis and Management of Steatotic Liver Disease
A multinational study published in Nature Communications Medicine demonstrates that LiverMultiScan can reduce liver biopsies, specialist consultations, and improve diagnosis rates for patients with metabolic dysfunction-associated steatotic liver disease (MASLD), proving cost-effective in Europe.
2025-03
Perspectum
Major Study Shows Liver Health Measured with cT1 Predicts Clinical Outcomes
A Nature Medicine study highlights that Perspectum's LiverMultiScan, specifically the iron-corrected T1 (cT1) metric, can predict cardiac and liver outcomes, supporting its use as an alternative to liver biopsy and for evaluating new metabolic treatments.
2025-05
Perspectum
New Published Data Show Reproducibility and Utility of Perspectum's MRI in Patients With Metabolic Liver Disease
Perspectum announced two new research studies affirming the utility of quantitative MRI imaging, including LiverMultiScan, as a noninvasive alternative to liver biopsy for diagnosing and monitoring metabolic dysfunction-associated steatohepatitis (MASH) in clinical trials and patient care.
2024-09
Perspectum
Perspectum Awarded New FDA Grant to Evaluate Biomarker for Rare Disease Drug Development
Perspectum, a leader in medical imaging quantification techniques, received an FDA grant to evaluate a biomarker for rare disease drug development.
2024-11
Business Wire
LiverMultiScan Shown to Be a Cost-Effective Alternative to Liver Biopsies for Monitoring Patients with Autoimmune Hepatitis - Business Wire
A health economic study published in BMJ Open found that Perspectum's LiverMultiScan is a cost-effective and non-invasive alternative to liver biopsies for monitoring autoimmune hepatitis patients, potentially saving significant healthcare costs.
2022-09
RAD Magazine
LiverMultiScan detects earlier stages of treatable disease in patients with autoimmune hepatitis, study shows - RAD Magazine
A study published in eClinicalMedicine (The Lancet) demonstrated that LiverMultiScan-cT1 improved autoimmune hepatitis management by identifying patients with active sub-clinical disease, even with normal blood markers, leading to more tailored clinical treatment.
2022-07
Perspectum
New meta-analysis finds Perspectum's non-invasive MRI biomarker cT1 is an effective alternative to biopsy for identifying patients at high risk of liver disease progression
A meta-analysis in Clinical Gastroenterology and Hepatology found that LiverMultiScan's cT1 biomarker accurately identifies NASH patients at high risk of disease progression, supporting its use as a non-invasive diagnostic tool.
2022-01
Business Wire
Perspectum Announces American Medical Association Issues Unique Category III CPTu00ae Codes for LiverMultiScanu00ae Quantitative Multiparametric MR - Business Wire
The American Medical Association (AMA) issued new Category III CPT codes for LiverMultiScan, a quantitative multiparametric MR exam, marking a significant reimbursement milestone that will expand patient access to this non-invasive liver disease diagnostic.
2021-01

Videos

Product demos, reviews, and walkthroughs for LiverMultiScan.

View all on YouTube

Frequently Asked Questions

LiverMultiScan employs AI-enhanced multiparametric MRI to quantify key liver metrics: proton density fat fraction (PDFF) for fat, T2* for iron, and iron-corrected T1 (cT1) for fibro-inflammation. This AI-driven analysis provides standardized, quantitative data that aids gastroenterologists in assessing disease activity, staging fibrosis, tracking progression, and personalizing treatment plans for chronic liver conditions.
LiverMultiScan is FDA 510(k) cleared in the U.S. and holds the CE Mark in Europe, indicating its compliance with medical device regulations. As a software application for medical image analysis and DICOM connectivity, it adheres to standards for handling patient data within clinical workflows.
LiverMultiScan offers a comprehensive assessment of liver fat, iron, and fibro-inflammation in a single MRI scan, providing a 'virtual biopsy' view of heterogeneous liver tissue. It demonstrates a higher technical success rate than FibroScan (98.1% vs. 85%) and has shown superior accuracy in differentiating fibrosis grades in certain patient subgroups.
LiverMultiScan has achieved nationwide payer coverage in the U.S. for diagnosing and managing NAFLD and other chronic liver diseases. It is reimbursed under CPT Code 0648T by several Medicare Administrative Contractors and is included in AIM Specialty Health's advanced imaging guidelines.
While generally accurate, LiverMultiScan adds approximately 15 minutes to a standard MRI scan, and some studies have shown only moderate association with steatosis or fibrosis stages in specific NAFLD patient comparisons. Its role in assessing liver health for malignant liver disease may be limited, and general AI limitations like data bias and the need for robust multicenter validation also apply.
LiverMultiScan operates as a standalone software application that processes non-contrast multiparametric MRI data, integrating into existing MRI exams and clinical workflows. It supports DICOM connectivity, allowing for seamless data transfer to PACS and other systems for archiving and distribution.
LiverMultiScan's AI-driven quantification of liver fat (PDFF) is considered a gold standard, and its iron-corrected T1 (cT1) measures fibro-inflammation, accounting for confounding iron effects. Validation studies have demonstrated good correlation of these metrics with liver biopsy findings across various liver disease etiologies, showing high accuracy in discriminating healthy individuals from those with fibrosis, steatosis, or iron overload.

Related Tools

Cologuard / Cologuard Plus
Exact Sciences
Gastroenterology AI
Cologuard and Cologuard Plus are FDA-approved, non-invasive stool DNA colorectal cancer screening tests from Exact Sciences for average-risk individuals aged 45 and older. Cologuard Plus offers enhanced accuracy and fewer false positives. These at-home tests detect DNA markers and blood in stool to identify early-stage colorectal cancer.
Most insured patients pay $0
Deep Capsule
Digestaid - Artificial Intelligence Development SA
Gastroenterology AI
Deep Capsule is an AI software tool that assists in reviewing capsule endoscopy images by detecting and differentiating lesions, stratifying hemorrhagic potential, and highlighting clinically relevant frames for physician validation.
Pure-Vu
Motus GI
Gastroenterology AI
The Pure-Vu System is an FDA-approved device that facilitates intra-procedural cleansing of the GI tract to improve visualization during colonoscopies and gastroscopies, especially in cases of inadequate bowel preparation or GI bleeding.
Paid
aScope Gastro
Ambu
Gastroenterology AI
The Ambu aScope Gastro is a sterile, single-use gastroscope with advanced imaging and design features for a variety of endoscopic procedures in the upper GI tract, offering portability and eliminating reprocessing.
Contact for pricing
CADDIE™ Computer-Aided Detection (CADe) Device
Odin Medical Ltd. (an Olympus Corporation company)
Clinical Decision Support & Reference
CADDIE™ is the first cloud-based AI technology to receive FDA clearance, designed to assist gastroenterologists in detecting suspected colorectal polyps during colonoscopy procedures. This AI tool, developed by Odin Medical Ltd., an Olympus Corporation company, supports real-time polyp detection and characterization, improves adenoma detection rates, and integrates seamlessly into existing clinical workflows.
Per procedure cost effectiveness
RSIP Vision AI Solutions for Gastroenterology
RSIP Vision
Gastroenterology AI
RSIP Vision offers advanced AI and computer vision technologies designed to enhance diagnostic accuracy and procedural efficiency in gastroenterology, though the dedicated product page is no longer active.

See all Gastroenterology AI tools →

More from Perspectum

Hepatica v1
Perspectum
Oncology AI
Hepatica v1 by Perspectum is an AI-driven clinical and surgical decision support tool that provides quantitative measurements and visualizations of liver health from MRI data, primarily for pre-surgical planning in liver cancer.
Contact vendor for pricing details; service is reimbursed by cms and covered by many commercial payers.
LiverMultiScan v5
Perspectum
Gastroenterology AI
LiverMultiScan v5 is an AI-powered, non-invasive MRI-based software that quantifies liver fat, iron, and fibroinflammation (cT1) to aid in the diagnosis and monitoring of chronic liver diseases.
Contact vendor for pricing.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-20 | First Added: 2026-04-20
AI Tool Finder
AI-powered search. Results may not be comprehensive.